The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Large‐scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide. The lack of effective biomarkers for the early detection of HCC results in unsatisfactory curative treatments. Here, metabolite biomarkers were identified and validated for HCC diagnosis. A total of 1,448 subjects, including healthy controls and patients with chronic hepatitis B virus infection, liver cirrhosis, and HCC, were recruited from multiple centers in China. Liquid chromatography–mass spectrometry–based metabolomics methods were used to characterize the subjects' serum metabolic profiles and to screen and validate the HCC biomarkers. A serum metabolite biomarker panel including phenylalanyl‐tryptophan and glycocholate was defined. This panel had a higher diagnostic performance than did α‐fetoprotein (AFP) in differentiating HCC from a high‐risk population of cirrhosis, such as an area under the receiver‐operating characteristic curve of 0.930, 0.892, and 0.807 for the panel versus 0.657, 0.725, and 0.650 for AFP in the discovery set, test set, and cohort 1 of the validation set, respectively. In the nested case–control study, this panel had high sensitivity (range 80.0%‐70.3%) to detect preclinical HCC, and its combination with AFP provided better risk prediction of preclinical HCC before clinical diagnosis. Besides, this panel showed a larger area under the receiver‐operating characteristic curve than did AFP (0.866 versus 0.682) to distinguish small HCC, and 80.6% of the AFP false‐negative patients with HCC were correctly diagnosed using this panel in the test set, which was corroborated by the validation set. The specificity and biological relevance of the identified biomarkers were further evaluated using sera from another two cancers and HCC tissue specimens, respectively. Conclusion: The discovered and validated serum metabolite biomarker panel exhibits good diagnostic performance for the early detection of HCC from at‐risk populations. (H epatology 2018;67:662‐675).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Trygg, J., Holmes, E., & Lundstedt, T. (2007) · Journal of Proteome Research · doi:10.1021/pr060594q · Cited by 1,273
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Holt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K. F., Donahee, M., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., et al. (2003) · Genes & Development · doi:10.1101/gad.1083503 · Cited by 696
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508 · cited 1×
“Increased levels of bile acids in the circulation are usually caused by elevated synthesis of bile acids or liver injury.((32,38)) Many studies have revealed that the synthesis of bile acids in malignant cancer cell is downregulated by fibroblast growth factor 19, which can promote carcinogenesis of the liver.”
BackgroundThe bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
Pols, T. W. H., Noriega, L. G., Nomura, M., Auwerx, J., & Schoonjans, K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.004 · Cited by 454
Song, K., Li, T., Owsley, E., Strom, S., & Chiang, J. Y. L. (2009) · Hepatology · doi:10.1002/hep.22627 · Cited by 414
Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics
Huang, Q., Tan, Y., Yin, P., Ye, G., Gao, P., Lu, X., Wang, H., & Xu, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0308 · Cited by 414
Self-citationSerum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma
Chen, T., Xie, G., Wang, X., Fan, J., Qiu, Y., Zheng, X., Qi, X., Cao, Y., Su, M., Wang, X., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004945 · Cited by 357
Self-citationA list of candidate cancer biomarkers for targeted proteomics.
Polanski, M., & Anderson, N. L. (2007) · PubMed Central · Cited by 350
Fiorucci, S., Mencarelli, A., Palladino, G., & Cipriani, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.001 · Cited by 346
Gilbert, E. R., Wong, E. A., & Webb, K. E. (2008) · Journal of Animal Science · doi:10.2527/jas.2007-0826 · Cited by 337
Walsh, M. C., Brennan, L., Malthouse, J. P. G., Roche, H. M., & Gibney, M. J. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.531 · Cited by 291
Cohort Profile: The Dongfeng–Tongji cohort study of retired workers
Wang, F., Zhu, J., Yao, P., Li, X., He, M., Liu, Y., Yuan, J., Chen, W., Zhou, L., Min, X., et al. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys053 · Cited by 286
Self-citationConsensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
Preanalytical Aspects and Sample Quality Assessment in Metabolomics Studies of Human Blood
Yin, P., Peter, A., Franken, H., Zhao, X., Neukamm, S. S., Rosenbaum, L., Lucio, M., Zell, A., Häring, H.-U., Xu, G., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.199257 · Cited by 272
Self-citationDysregulated hepatic bile acids collaboratively promote liver carcinogenesis
Xie, G., Wang, X., Huang, F., Zhao, A., Chen, W., Yan, J., Zhang, Y., Lei, S., Ge, K., Zheng, X., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30219 · Cited by 252
Self-citationRole of Nicotinamide in DNA Damage, Mutagenesis, and DNA Repair
Surjana, D., Halliday, G. M., & Damian, D. L. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/157591 · Cited by 251
Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects
Fonteh, A. N., Harrington, R. J., Tsai, A., Liao, P., & Harrington, M. G. (2007) · Amino Acids · doi:10.1007/s00726-006-0409-8 · Cited by 250
Comprehensive Metabolomic Characterization of Coronary Artery Diseases
Fan, Y., Li, Y., Chen, Y., Zhao, Y.-J., Liu, L.-W., Li, J., Wang, S.-L., Alolga, R. N., Yin, Y., Wang, X.-M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.044 · Cited by 247
Self-citationChen, S., Kong, H., Lu, X., Li, Y., Yin, P., Zeng, Z., & Xu, G. (2013) · Analytical Chemistry · doi:10.1021/ac4016787 · Cited by 235
Self-citationSoga, T., Sugimoto, M., Honma, M., Mori, M., Igarashi, K., Kashikura, K., Ikeda, S., Hirayama, A., Yamamoto, T., Yoshida, H., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.031 · Cited by 234
Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma
Wang, X., Zhang, A., & Sun, H. (2013) · Hepatology · doi:10.1002/hep.26130 · Cited by 223
Self-citationDistinctly altered gut microbiota in the progression of liver disease
Xie, G., Wang, X., Liu, P., Wei, R., Chen, W., Rajani, C., Hernandez, B. Y., Alegado, R., Dong, B., Li, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8466 · Cited by 219
Self-citationPathways and functions of gut microbiota metabolism impacting host physiology
Krishnan, S., Alden, N., & Lee, K. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.08.015 · Cited by 212
Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage
Tummala, K. S., Gomes, A. L., Yilmaz, M., Graña, O., Bakiri, L., Ruppen, I., Ximénez-Embún, P., Sheshappanavar, V., Rodriguez-Justo, M., Pisano, D. G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.002 · Cited by 206
Luo, P., Dai, W., Yin, P., Zeng, Z., Kong, H., Zhou, L., Wang, X., Chen, S., Lu, X., & Xu, G. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00615 · Cited by 187
Self-citationSeparating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183
Self-citationNewer markers for hepatocellular carcinoma
Marrero, J. A., & Lok, A. S. F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.024 · Cited by 175
Tan, Y., Yin, P., Tang, L., Xing, W., Huang, Q., Cao, D., Zhao, X., Wang, W., Lu, X., Xu, Z., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010694 · Cited by 156
Self-citationThe Long Journey of Cancer Biomarkers from the Bench to the Clinic
Pavlou, M. P., Diamandis, E. P., & Blasutig, I. M. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.184614 · Cited by 150
Liu, Y., Hong, Z., Tan, G., Dong, X. W., Yang, G., Zhao, L., Chen, X., Zhu, Z., Lou, Z., Qian, B., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28706 · Cited by 138
Zeng, J., Yin, P., Tan, Y., Dong, L., Hu, C., Huang, Q., Lu, X., Wang, H., & Xu, G. (2014) · Journal of Proteome Research · doi:10.1021/pr500390y · Cited by 132
Self-citationDent, P., Fang, Y., Gupta, S., Studer, E. J., Mitchell, C., Spiegel, S., & Hylemon, P. B. (2005) · Hepatology · doi:10.1002/hep.20942 · Cited by 125
Fitian, A. I., Nelson, D. R., Liu, C., Xu, Y., Ararat, M., & Cabrera, R. (2014) · Liver International · doi:10.1111/liv.12541 · Cited by 125
Shao, Y., Zhu, B., Zheng, R., Zhao, X., Yin, P., Lu, X., Jiao, B., Xu, G., & Yao, Z. (2014) · Journal of Proteome Research · doi:10.1021/pr500973d · Cited by 123
Self-citationSerum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis
Wang, X., Xie, G., Zhao, A., Zheng, X., Huang, F., Wang, Y., Yao, C., Jia, W. P., & Liu, P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00217 · Cited by 119
Self-citationProteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review
Kimhofer, T., Fye, H. K. S., Taylor-Robinson, S. D., Thursz, M. R., & Holmes, E. C. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.38 · Cited by 117
Chen, Y., Song, X., Valanejad, L., Vasilenko, A., More, V. R., Qiu, X., Chen, W., Lai, Y., Slitt, A. L., Stoner, M. A., et al. (2012) · Hepatology · doi:10.1002/hep.26187 · Cited by 89
Self-citationLadep, N. G., Dona, A. C., Lewis, M. R., Crossey, M. M. E., Lemoine, M., Okeke, E. N., Shimakawa, Y., Duguru, M. J., Njai, H. F., Fye, H. K. S., et al. (2014) · Hepatology · doi:10.1002/hep.27264 · Cited by 82
Luo, P., Yin, P., Zhang, W., Zhou, L., Lu, X., Lin, X., & Xu, G. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.01.078 · Cited by 69
Self-citationPhenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach
Liang, Q., Liu, H., Wang, C., & Li, B. (2016) · Scientific Reports · doi:10.1038/srep19763 · Cited by 46
Circulating Biomarkers in Bladder Cancer
Nandagopal, L., & Sonpavde, G. (2016) · Bladder Cancer · doi:10.3233/blc-160075 · Cited by 31
Cited by
Harnessing multimodal data integration to advance precision oncology
Boehm, K. M., Khosravi, P., Vanguri, R., Gao, J., & Shah, S. P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00408-3 · Cited by 662
Zheng, F., Zhao, X., Zeng, Z., Wang, L., Lv, W., Wang, Q., & Xu, G. (2020) · Nature Protocols · doi:10.1038/s41596-020-0341-5 · Cited by 272
Self-citationMetabolomic machine learning predictor for diagnosis and prognosis of gastric cancer
Chen, Y., Wang, B., Zhao, Y., Shao, X., Wang, M., Ma, F., Yang, L., Nie, M., Jin, P., Yao, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46043-y · Cited by 244
Self-citationCurrent and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Self-citation
Metadata
- Authors
- Luo, P., Yin, P., Hua, R., Tan, Y., Li, Z., Qiu, G., Yin, Z., Xie, X., Wang, X., Chen, W., Zhou, L., Wang, X., Li, Y., Chen, H., Gao, L., Lu, X., Wu, T., Wang, H., Niu, J., & Xu, G.
- Venue
- Hepatology
- Published
- 2018-01-02
- Volume
- 67
- Issue
- 2
- Pages
- 662-675
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2758971543
- Cited by
- 370
- References
- 49
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.